Mindpeak vs Visiopharm
These two overlap most directly, both CE marked immunohistochemistry scorers covering HER2, Ki-67, and PD-L1 with no FDA clearance, so the decision comes down to distribution philosophy and where the evidence sits. If you want algorithms that follow your laboratory across whatever workspace you run and rest on independent validation, start with Mindpeak. If your laboratory standardizes on Agilent assays and you want the broadest certified portfolio, start with Visiopharm. Mindpeak is platform portable, embedded in PathAI, and is the rare vendor here with genuinely independent third party evidence. Visiopharm is coupled to Agilent as its Diagnostic Package, holds the deepest run of IVDR clearances, and can point to a named, quantified deployment reporting real time and cost savings.
- Independent validation: third party studies, including work by Abele and colleagues and a concordance study at Aga Khan University Hospital, rather than only vendor run or single deployment evidence.
- Platform portable and assay neutral: embedded in PathAI's AISight and tied to no assay maker, so the algorithms follow the laboratory rather than a specific assay line.
- Cell level breast depth: BreastIHC distinguishes tumor from non tumor structures at the cellular level, in the highest volume biomarker workload.
- The deepest certified portfolio: the PD-L1 APP is its ninth IVDR clearance, and coverage extends beyond scoring to metastasis and invasive tumor detection across breast, lung, prostate, and colorectal cancer.
- A named, quantified deployment: at UMC Utrecht inside a Sectra system, reporting increased metastasis detection sensitivity, roughly 35 percent time saved, and reduced immunohistochemistry cost.
- Assay integrated for Agilent laboratories: validated to Agilent assays and the Omnis platform and sold as the Visiopharm Diagnostic Package.
Side-by-Side
| Axis | M Mindpeak |
V Visiopharm |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Both are CE-IVD only with no FDA clearance, and neither publishes pricing, a security attestation, or demographic subgroup analysis, though Visiopharm's three site validation is a partial answer to generalization. Visiopharm's prostate APP carries the older IVDD mark through its DeepBio supplier rather than IVDR, and its coupling to Agilent is a benefit for Agilent shops and a constraint for others. Mindpeak's clinical coverage is narrower than its product list implies, since its prostate and other assays are research use only, and because its algorithms run inside a third party platform, data residency and stewardship follow the host rather than Mindpeak. Both report concordance and efficiency evidence rather than patient outcomes.